Liver-expressed Antimicrobial Peptide 2, Control Peptide (LEAP-2)

Human genome contains numerous genes whose protein products are unknown in terms of structure, interaction partner, expression, and function.

From human blood ultrafiltrate, a novel gene-encoded, cysteine-rich, and cationic peptide termed as liver- expressed antimicrobial peptide 2 (LEAP-2) together with several circulating forms of LEAP-2 differing in their amino-terminal length were identified, all containing a core structure with two disulfide bonds formed by cysteine residues in relative 1-3 and 2-4 positions. The largest native LEAP-2 form of 40aa residues is generated from the precursor at a putative cleavage site for a furin-like endoprotease. In contrast to smaller LEAP-2 variants, this peptide exhibited dose-dependent antimicrobial activity against selected microbial model organisms.

LEAP2: rat= 75aa; mouse= 76aa; human= 77aa; Human chromosome: 5q31.1. Protein homology between mose, rat and human LEAP2 is 99%. LEAP2 is expressed in liver, blood, urine and kidney.

Source:
Synthetic peptide corresponding to 20aa of human LEAP-2, C-terminal.

Molecular Weight:
~3kD

Applications:
Suitable for use in ELISA and Antibody Blocking. Not suitable for Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 5-10ug control peptide per 1ug of aff pure IgG or 1ul antiserum
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.